NATICK, Mass., April 8, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, announced today that Michael Kauffman, Chief Executive Officer, is scheduled to present a company overview at the 13th Annual Needham Healthcare Conference. The conference is being held at The Westin Grand Central Hotel in New York City. The presentation is scheduled for Wednesday, April 9, 2014 at 8:00 am EDT.
The presentation will be webcast at the time of the presentation and can be accessed at http://wsw.com/webcast/needham65/KPTI. A replay of the webcast will be archived on the Investors page of the Company's website at www.karyopharm.com for 30 days following the presentation.
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitors of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). The inhibition of XPO1 by Karyopharm's lead drug candidate, Selinexor (KPT-330), a first-in-class, oral SINE compound, leads to the accumulation of tumor suppressor proteins in the cell nucleus, which subsequently reinitiates and amplifies their tumor suppressor function. This is believed to lead to the selective induction of apoptosis in cancer cells, while largely sparing normal cells. SINE compounds have shown biological activity in models of cancer, autoimmune disease, certain viruses, and wound-healing. Karyopharm was founded by Dr. Sharon Shacham and is located in Natick, Massachusetts.
CONTACT: Paul Brannelly Paul@karyopharm.com 508-975-4820 or Jennifer McNealey firstname.lastname@example.org 917-392-3400